Axol Bioscience Ltd.’s Post

axoCells™ motor neurons - the first choice for functional human iPSC-derived cells to power your in vitro ALS models. **In stock** Ready to ship** Email operations@axolbio.com When you're looking for a high-quality source of iPSC-derived motor neurons, what does better look like? Correct morphology? Key markers? Functional relevance on electrophysiology? Characterization in advanced in vitro models? How about all of the above?! We've spent the last decade developing our manufacturing capabilities to produce robust, consistent, functionally-relevant axoCells iPSC-derived motor neurons. And recently we have launched our axoCells ALS toolbox to further support the industry in it’s fight against ALS and accelerate motor neuron research. The key features that can supercharge your research include: -Rapid maturation: Assay ready in just 10 days -Phenotypic relevance: Extensive characterization including morphology and key marker expression (HB9, MAP2, LIM3 and ChAT2) -Functional relevance: Validation of functional activity across multiple assay platforms including electrophysiology and calcium imaging with disease phenotypes -Confidence: Manufactured in our ISO 9001-accredited production facility with excellent ISSCR compliance, enabling you to confidently carry out your in vitro workflow -With our axoCells ALS toolbox containing functional motor neurons from 6 iPSC donor lines representing the main ALS-associated mutations (SOD1, TDP43 and C9orf72) and ongoing work towards functional QC as standard, we've become the first choice for researchers looking to access high-quality, functional motor neurons for ALS research and drug discovery. Take a look at our new Modelling ALS with iPSC-derived cells document to learn more: https://hubs.la/Q02SRxtd0 Looking for advice, support or products for your in vitro ALS research? Get in touch at operations@axolbio.com #iPSCs #MotorNeurons #ALS #DrugDiscovery #StemCells

It's Stem Cell Awareness Day! Since they were first generated in 2006 by Nobel Prize Winner Shinya Yamanaka, Induced Pluripotent Stem Cells (iPSCs) have been revolutionizing the in vitro drug discovery field. From being initially generated by introducing reprogramming factors using integrating viral vectors to now using non-integrating methods to make iPSCs more clinically applicable, there has been significant progress. As a result, human iPSCs are being used for disease modeling, drug discovery, and cell therapy development. As leaders in manufacturing iPSC-derived cells consistently and at scale, we see first-hand the role iPSCs have been playing in building better human relevant models of disease to accelerate and de-risk drug discovery. There is no doubt that in science, nothing is ever finished, there is constant evolution with everything, including stem cells! But we want to ask you, what are your thoughts on the development of this technology so far? What do you hope to see in the future? Let us know in the comments! Also if you would like to learn more about iPSCs and how you too can use them to support your research, feel free to contact us today at operations@axolbio.com! #humaniPSCs #stemcellawareness #drugdiscovery

iPSCs are becoming a key tool in the fight against Cardiovascular Diseases The iPSC revolution continues to extend across multiple disease areas with Cardiovascular disease (CVD) being among them. It is no doubt that CVDs are a major healthcare burden and while there has been significant progress in the field, there continues to be a rise in heart failure cases. The race to develop new therapies to tackle these diseases has also been met with roadblocks as many of these have had an alarmingly high failure rate. As mentioned in Wu et al, approximately 9 out of 10 drugs entering clinical trials have failed in the last 30 years. This indicates an urgent need for novel interventions including treatment innovation and overall care of CVD patients. One of the primary causes of the high failure rates has been largely attributed to the reliance of animal models in drug testing and safety evaluations. Given the translational differences between these models and human cardiovascular physiology, better models are needed. It is great to see iPSCs gaining recognition particularly in the drug discovery and development process for CVDs. Wu et al highlighted several ways iPSCs are being used from accelerating drug development in the era of the Food and Drug Administration Modernization Act 2.0 to iPSC modeling of ‘heart disease in-a-dish’. In particular, their review highlighted several cases where iPSC–guided drug discovery offered a precise and screenable approach for the industry. For example, they mentioned how a study was conducted to perform a functional screen of 2,464 compounds in iPSC-cardiomyocytes stimulated with remdesivir (a COVID-19 drug) in order to investigate and resolve cardiotoxicity induced by COVID-19 treatments. While there remain some challenges in the widespread adoption of iPSC technology, these developments display significant strides in their favor. With every challenge comes an opportunity and at Axol Bioscience, our 10-year expertise on the field, commitment to collaboration and effort in continuously listening to the needs of our community, we remain as one of those on the frontline doing our part to drive CVD research forward using human-iPSCs. We hope to see more progress in the field. To read the full paper click here: https://hubs.la/Q02SQWsj0 If you are looking to develop better models for cardiovascular disease our axoCells cardiomyocytes are frequently used to fuel in vitro cardiotoxicity models to assess drug safety and for cardiac research, and can be used in co-culture with other cells. Contact us to find out more, operations@axolbio.com. #iPSCs #Cardiomyocytes #CardiovascularDiseases

Great science, great collaborators and great conference freebies at Axion BioSystems ! With Teodora Popovici and Stacie Chvatal #sfn #conference #neuroscience

Collaboration in full show! Today, we welcomed Eline van Alfen, Supplier Manager from our distribution partner Bio-Connect BV to the Axol stand. Bio-Connect are our valued partner supporting researchers in the Benelux region through the supply of iPSC-derived cells. This interaction highlights the importance of collaboration in driving our success. Together, we can achieve great things! Don't forget to come say hello to us at booth #1370! Also for super easy ordering in the Benelux region, be sure to contact Bio-Connect directly at info@bio-connect.nl If you have any questions, please do not hesitate to contact us at operations@axolbio.com. #Neuroscience2024 #HumaniPSCs #DrugDiscovery #Collaboration

It's #techtuesday and today we are right in the thick of it at SfN Neuroscience 2024, Chicago. Our amazing team is at Booth #1370 and will be willing to give a tip or two especially when it relates to the wonderful world of human iPSCs. We look forward to seeing you at the event and answering your questions! Won't be attending Neuroscience 2024? Not to worry, you can always send your questions to operations@axolbio.com. We'll be happy to help! #techtuesday #iPSCs #Neuroscience2024 #SfN

Come by SfN booth #1370 for a happy snap! We're doing Polaroid photos, a nice record of your time at SfN Neuroscience 2024. Also, with so many posters at the show (and such a short time to see them) we've pinned up two of our posters on the stand. 1. Establishing a robust platform for investigating the pro- and anti-inflammatory response of iPSC-derived microglia in drug discovery presented by David Wallbank 2. Advancing neuromuscular junction modeling with compartmentalized microfluidic platforms coupled with MEA functional analysis presented in conjunction with NETRI, authored by Benoît Maisonneuve and Stuart Prime iPSCs are driving forward neuroscience drug discovery, better models of neurodegenerative diseases that are human-relevant. Come by the booth for a chat. We can't wait to speak with you! Couldn't make it to Neuroscience 2024? Don't worry, you can also email us at operations@axolbio.com if you'd like to ask us anything. Duncan Borthwick PhD Sian Humphreys David Wallbank Teodora Popovici #iPSC #SfN #Neuroscience2024 #collaboration

Thanks for joining us at ELRIG Drug Discovery 2024: A huge thank you to everyone who stopped by our booth - it was great being able to connect with many of you and share the work we do at Axol Bioscience in the iPSC space. If you missed our presentations or want to revisit any of the information, not to worry, our posters are available for download: One of the posters that was presented (Poster #9) was by Dr. Steven Broadbent, our Senior Scientific Support Manager titled: Validation of a cortical tri culture axoModel™ for in vitro compound screening a blinded compound study. With advanced in vitro models gaining traction in drug discovery, this poster represents a true landmark in the iPSC space. In this poster, we demonstrate the use of axoCells™ cortical excitatory neurons, inhibitory interneurons and astrocytes to produce a cortical tri-culture model. This model was tested against a blinded panel of compounds to validate it for neurotoxicity screening. This work, produced in partnership with Sumitomo Pharma America Inc., demonstrates the exciting potential for advanced in vitro models in drug discovery and safety pharmacology. Download the poster here: https://hubs.la/Q02SmbVj0 Also if there is anything you would like to follow-up with us on from ELRIG, be sure to get in contact with us at operations@axolbio.com, we'd be happy to have a conversation! #iPSCs #ELRIG #DrugDiscovery2024 #NeurodegenerativeResearch #AlzheimersDisease #DrugDiscovery #TriCulture

We're here at SfN Neuroscience 2024! Booth #1370 and ready to talk stem cells! How are in vitro models are shaping neuroscience your drug discovery and how can we help? Come check out our latest motor neuron news and our new poster: Poster #B67: Establishing a robust platform for investigating the pro- and anti-inflammatory response of iPSC-derived microglia in drug discovery presented by David Wallbank We can't wait to speak with you! Couldn't make it to Neuroscience 2024? Don't worry, you can also email us at operations@axolbio.com if you'd like to ask us anything. See you at Booth #1370! Duncan Borthwick PhD Liam Taylor Oliver Richardson Sian Humphreys David Wallbank Teodora Popovici #neuroscience2024 #humaniPSCs #drugdiscovery #collaboration

We're here at SfN Neuroscience 2024! Our team are all set up at Booth #1370 and ready to meet with you! Our Senior Scientist, David Wallbank, is presenting a poster showcasing our work on the pro- and anti-inflammatory responses of iPSC-derived microglia in drug discovery. Microglia are the main inflammatory cell of the brain and have been implicated in the development and progression of several neuroinflammatory and neurodegenerative conditions such as Alzheimer's disease (AD), Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS). iPSC-derived microglia provide a scalable, reproducible and physiological relevant model with which to study this role. Axol Bioscience has developed a robust protocol to generate microglia, with over 30 lines successfully differentiated, including those derived from healthy and patient donors and gene-edited lines. Poster number: #B67 Presentation time: 11 AM David will be available to answer any questions you have, or you can find him at Booth #1370 after the presentation. Couldn't make it to Neuroscience 2024? Don't worry, you can also email us at operations@axolbio.com if you'd like to ask us anything. #neuroscience2024 #humaniPSCs #drugdiscovery #collaboration